Sage Therapeutics Stock Rockets on Two Positive Phase III Trials in Postpartum Depression Post author:Sam Post published:November 8, 2017 Post category:BioPharma The positive results support the company’s planned regulatory submissions. Source: BioSpace You Might Also Like AstraZeneca PLC Jumps Deeper Into mRNA Drugs With Ethris Deal August 20, 2017 Veloxis Pharma Increases Share Capital In Connection With Exercise Of Warrants September 11, 2017 Sihuan Pharma Opens Up R&D Shop in the San Francisco Bay Area August 14, 2017
